Petal Bio Secures Series A Funding Led by Jinding Capital to Advance Agarose-Based Aesthetic Filler

Recently, Shanghai Huaban Biotechnology Co., Ltd. (hereinafter referred to as “Huaban Biotech”) completed its first round of financing amounting to tens of millions of yuan, with Jinding Capital as the sole investor.This round of financing will provide significant support for the commercialization and technological R&D of Huaban Biotechnology’s core product, “Anroumei” agarose gel, marking a new stage of development for the company in the field of medical aesthetics materials.

Shanghai Huaban Biotechnology Co., Ltd. was established in November 2023, specializing in the innovative research and development of new materials for medical aesthetics.The company’s core product, “Anroumei” agarose gel, is the first independently developed injectable agarose filler in China. It features high safety, softness, and hydrophobicity, effectively avoiding the “pillow face” effect caused by water absorption in traditional medical aesthetic materials. With its “what you see is what you get” immediate shaping capability and low risk of embolism, agarose fillers are becoming the new benchmark for next-generation injectable dermal fillers.

This round of financing will provide strong support for Huaban Biotechnology to further expand the application of agarose technology.Over the next three years, the Company will deepen the combined application of agarose with other materials (e.g., agarose + hydroxyapatite), continuously refine its product pipeline, and promote clinical validation and market expansion of “Anroumei” across more specialized segments. Furthermore, the Company plans to further enhance its R&D capabilities and maintain its technological leadership in the industry by expanding its R&D team and optimizing production processes.

Meanwhile, Huaban Biotechnology will continue to focus on product innovation and technological upgrades, building an international platform for technological innovation.On the market front, the company will help medical aesthetic institutions and physicians better master and promote the use of new materials through professional education and training, physician empowerment, and after-sales support, thereby delivering a higher-quality service experience to consumers.

As the medical aesthetics industry continues to advance toward standardization and high-quality development, consumer demand for safe and efficient medical aesthetic materials continues to rise.Leveraging the core competitiveness of agarose as an innovative material, Shanghai Huaban Biotechnology Co., Ltd. has emerged as a key representative of innovation in the medical aesthetics industry. Its products not only provide novel solutions to address the pain points of existing medical aesthetic materials but also inject strong momentum into the technological advancement of the global medical aesthetics sector.

About This Round of FinancingLiu Yandong, Founder and CEO of Huaban Biotechnologystated: “We extend our gratitude to Jinding Capital for its support of Huaban Biotechnology. We aim to empower the sustainable development of the medical aesthetics industry through technological innovation and high-quality products. Looking ahead, Huaban Biotechnology will continue to be driven by scientific research, establishing a strong foothold in China while expanding its global presence. We are committed to becoming an innovative hallmark of China’s medical aesthetics industry, providing consumers worldwide with superior and safer medical aesthetic solutions.”

Jinding Capital Investment Teamstated: “The safety and innovation of agarose materials have injected new vitality into the medical aesthetics industry. Compared with hyaluronic acid, agarose offers superior biocompatibility, hydrophobicity, and a lower risk of embolism, making it a key direction for next-generation injectable fillers. As the first enterprise in China to independently develop agarose-based fillers, Shanghai Huaban Biotechnology Co., Ltd. holds significant advantages in technological leadership and market insight. We believe that Huaban Biotechnology will further drive the innovative development of new materials in China’s medical aesthetics sector and become a major force in the industry.”